Organisation paid for research Program year 2025 Source: CMS Open Payments

Asthma and Allergy Associates, PC

Neither a doctor nor a teaching hospital

Research payments

$1,318,140

75 payments

Through program year 2025, Asthma and Allergy Associates, PC is reported as receiving $1,318,140 in research payments, across 75 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $424,201 16
2024 Research $443,364 12
2023 Research $198,203 17
2022 Research $80,661 10
2021 Research $32,390 2
2020 Research $38,717 7
2019 Research $100,604 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $910,541 21 payments
  2. Novartis Pharmaceuticals Corporation $178,454 16 payments
  3. Eli Lilly and Company $106,314 7 payments
  4. Sanofi US Services Inc. $67,840 19 payments
  5. Teva Pharmaceuticals USA, Inc. $36,690 9 payments
  6. Adare Pharmaceuticals, Inc. $7,500 1 payment
  7. Amgen Inc. $5,927 1 payment
  8. Chiesi USA, Inc. $4,875 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States $335,829 3 payments
  2. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $243,144 3 payments
  3. ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart $127,267 5 payments
  4. A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $121,638 2 payments
  5. aumlticentre,randomised,open label,parallel group,phase IIIb study to assess the potential for tezepelumab treatedtie pants with severe asthma to reduce background therapy while sustaining asthma control and clinical remission $102,332 2 payments
  6. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $80,680 4 payments
  7. A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma $63,940 18 payments
  8. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $60,768 2 payments
  9. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $45,546 5 payments
  10. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $36,690 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record